. Inserm-cépidc, Centre d'épidémiologie sur les causes médicales de décès) Principales causes de décès en, 2008.

K. M. Foley, Advances in pain research and therapy, pp.59-75, 1979.

R. Gonin, A. Hatfield, J. Edmonson, R. Blum, J. Stewart et al., Pain and its treatment in outpatients with metastatic cancer cleeland CS, pp.592-596, 1994.

. Pert and . Snyder, 17-Properties of opiate-receptor binding in rat brain, 1973.

W. R. Martin, C. G. Eades, J. M. Thompson, R. E. Huppler, and G. P. , The effects of morphine-and nalorphine-like drugs in the non-dependent chronic spinal dog

T. Walsh and C. Saunders, 27-morphine kinetics in cancer patients, NEJM J. Sawe,B. Dahlstrom, Paalzow L clinical pharmacology and therapeutics, vol.305, issue.305, pp.1417-1418629, 1981.

O. Standards, sur les traitements antalgiques médicamenteux des douleurs cancéreuses par excès de nociception chez l'adulte Bulletin du Cancer, Août 2003, Standards, Options et Recommandations 30-Oral morphine for cancer pain Wiffen PJ, Mc QUAY HJ Cochrane data batabase systematic review, pp.795-806, 2002.

R. Poyhia, T. Seppala, K. Olkkola, and E. Kalso, The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects., British Journal of Clinical Pharmacology, vol.66, issue.6
DOI : 10.1111/j.1600-0773.1990.tb00737.x

N. Olson, A. Colon, J. Rivera, R. Kaiko, and R. Fitzmartin, Analgesic efficacy of controlled-release oxycodone in postoperative pain Sunshine A

J. Mandema, R. Kaiko, B. Oshlack, R. Reder, and D. Stanski, 37-Characterization and validation of a pharmacokinetic model for controlled-release oxycodone

D. Dupoiron, D. Lefebvre-kuntz, O. Brenet, S. De-bourmont, F. Grelon et al., François Bore, Dominique Monnin Douleurs Évaluation -Diagnostic -Traitement, Intrathecal Drug Delivery, pp.140-146, 2008.

O. Mahony, S. Coyle, N. Payne, and R. , Current management of opioid-related side effects, Oncology, vol.15, pp.61-77, 2000.

Y. Agra, A. Sacristan, M. Gonzalez, and M. Ferrari, Efficacy of senna versus lactulose in terminal cancer patients treated with opioids, Journal of Pain and Symptom Management, vol.15, issue.1
DOI : 10.1016/S0885-3924(97)00276-5

J. Culpepper-morgan, C. Inturrisi, R. Portenoy, K. Foley, R. Houde et al., Treatment of opioid-induced constipation with oral naloxone: A pilot study, Clinical Pharmacology and Therapeutics, vol.52, issue.1, pp.90-95, 1992.
DOI : 10.1038/clpt.1992.106

W. Meissner, U. Schmidt, M. Hartmann, R. Kath, and K. Reinhart, Oral naloxone reverses opioid-associated constipation, Pain, vol.84, issue.1, pp.105-109, 2000.
DOI : 10.1016/S0304-3959(99)00185-2

L. Latasch, M. Zimmermann, and B. Eberhardt, Aufhebung einer Morphin- induzierten Obstipation durch orales Naloxon, Der Anaesthesist, vol.46, issue.3, pp.191-194, 1997.
DOI : 10.1007/s001010050390

H. A. Parsons, M. De-la-cruz, Z. Osta, B. Li, J. L. Calderon et al., Methadone initiation and rotation in the outpatient setting for patients with cancer pain, Cancer, vol.11, issue.3, pp.520-528, 2010.
DOI : 10.1081/CNV-50482

P. Treatment, . Of, M. H. Pain, and . Levy, Number 15 pp 1124-1132 The New England Journal of Medicine 86-Opioid Rotation for Toxicity Reduction In Terminal Cancer Patients Noémi D. de Stoutz, J Pain Symptom Manage, vol.33510, pp.378-384, 1995.

. Frequency, Indications, Outcomes, and Predictive Factors of Opioid Switching in an Acute Palliative Care Unit Sebastiano Mercadante, J Pain Symptom Manage, vol.37, pp.632-641, 2009.

N. Donald, L. Der, A. , and S. , Opioid hyperexcitability: the application of alternate opioid therapy Mac, Pain, pp.53-353, 1993.

P. G. Fine and R. K. Portenoy, Establishing ???Best Practices??? for Opioid Rotation: Conclusions of an Expert Panel, Journal of Pain and Symptom Management, vol.38, issue.3, pp.418-443, 2009.
DOI : 10.1016/j.jpainsymman.2009.06.002

H. Knotkova, P. G. Fine, and R. K. Portenoy, Opioid Rotation: The Science and the Limitations of the Equianalgesic Dose Table, Journal of Pain and Symptom Management, vol.38, issue.3, pp.426-465, 2009.
DOI : 10.1016/j.jpainsymman.2009.06.001

G. Hanks, R. Portenoy, N. Macdonald, and K. Foley, 101-. Difficult pain problems

M. P. Davis, D. Walsh, B. Dhawan, F. Cesselin, R. Raghubir et al., 73-83 Classification of opioid receptors, support care cancer International Union of Pharmacology. XII.. Pharmacol Rev, vol.948, issue.4, pp.567-592, 1996.

E. Bruera, J. J. Franco, and M. Maltoni, Changing pattern of agitated impaired mental status in patients with advanced cancer: Association with cognitive monitoring, hydration, and opioid rotation, Journal of Pain and Symptom Management, vol.10, issue.4, pp.287-291, 1995.
DOI : 10.1016/0885-3924(95)00005-J

N. B. Eddy and M. D. , 107-Synthetic substances with morphine-like effect Relationship between Analgesic Action and Addiction Liability, with a Discussion of the Chemical Structure of Addiction-Producing Substances, Bull. Org. mond. Sante, vol.14, pp.353-402, 1956.

. Methadone, History and recommendations for use in Analgesia, APS Bull, 2000.

H. ?-commission-de-la-transparence, Avis du 31 janvier 2007 et du 19 décembre 2007 concernant respectivement le chlorhydrate de méthadone en sirop et la méthadone en gélules

R. Portenoy and K. Foley, Chronic use of opioid analgesics in non-malignant pain: Report of 38 cases, Pain, vol.25, issue.2, pp.171-86, 1986.
DOI : 10.1016/0304-3959(86)90091-6

. Opioid, T. Reisine, and G. Pasternak, Goodman and Gilman's The Pharmacologic Basis of Therapeutics, pp.521-55

. Ketobemidone, B. Ebert, S. Anderson, and P. Krogsgaard-larsen, methadone and pethidine are noncompetitive N-methyl-d aspartate (NMDA) antagonists in the rat cortex and spinal, pp.553-562, 1998.

E. Bruera and C. Sweeney, Methadone Use in Cancer Patients with Pain: A Review, Journal of Palliative Medicine, vol.5, issue.1, pp.127-165, 2002.
DOI : 10.1089/10966210252785097

J. Duche, S. Urien, and N. Simon, Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer, Clinical Biochemistry, vol.33, issue.3, pp.197-202, 2000.
DOI : 10.1016/S0009-9120(00)00048-5

T. Bjornsson, J. Callaghan, and H. Einolf, THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE, Drug Metabolism and Disposition, vol.31, issue.7, pp.815-847, 2003.
DOI : 10.1124/dmd.31.7.815

S. Fishman, B. Wilsey, G. Mahajan, and P. Molina, Methadone Reincarnated: Novel Clinical Applications with Related Concerns, Pain Medicine, vol.3, issue.4, pp.339-387, 2002.
DOI : 10.1046/j.1526-4637.2002.02047.x

S. Mercadante, F. Fulfaro, and M. Dabbene, Support Care Cancer, pp.129-159, 2001.

C. Ripamonti and M. Bianchi, The use of methadone for cancer pain, Hematology/Oncology Clinics of North America, vol.16, issue.3, pp.543-555, 2002.
DOI : 10.1016/S0889-8588(02)00017-5

M. Garrido, C. Aguirre, J. Troconiz, M. Marot, N. Valle et al., Alpha1-acid glycoprotein (AAG) and serum protein binding of methadone in heroin addicts with abstinence syndrome, Int. Journal of Clinical Pharmacology and Therapeutics, vol.38, issue.01, pp.35-40, 2000.
DOI : 10.5414/CPP38035

C. Inturrisi, W. Colburn, and R. Kaiko, Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain, Clinical Pharmacology and Therapeutics, vol.41, issue.4
DOI : 10.1038/clpt.1987.47

S. Fishman, B. Wilsey, G. Mahajan, and P. Molina, Methadone Reincarnated: Novel Clinical Applications with Related Concerns, Pain Medicine, vol.3, issue.4, pp.339-387, 2002.
DOI : 10.1046/j.1526-4637.2002.02047.x

C. Eap, G. Bertschy, P. Baumann, T. Finkbeiner, M. Gastpar et al., High Interindividual Variability of Methadone Enantiomer Blood Levels to Dose Ratios, Archives of General Psychiatry, vol.55, issue.1
DOI : 10.1001/archpsyc.55.1.89

J. Kolars, K. Lown, P. Schmiedlin-ren, M. Ghosh, C. Fang et al., CYP3A gene expression in human gut epithelium, CYP3A gene expression in human gut epithelium, pp.247-259, 1994.
DOI : 10.1097/00008571-199410000-00003

G. Gourlay, D. Cherry, and M. Cousins, A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer, Pain, vol.25, issue.3, pp.297-312, 1986.
DOI : 10.1016/0304-3959(86)90234-4

K. Verebely, J. Volavka, S. Mule, and R. Resnick, Methadone in man: Pharmacokinetic and excretion studies in acute and chronic treatment, Clinical Pharmacology & Therapeutics, vol.18, issue.2, pp.180-190, 1975.
DOI : 10.1002/cpt1975182180

C. Felder, C. Vehlinger, P. Baumann, and K. Powell, Oral and intravenous methadone use: some clinical and pharmacokinetic aspects, Drug and Alcohol Dependence, vol.55, issue.1-2, pp.137-143, 1999.
DOI : 10.1016/S0376-8716(98)00190-2

R. Fainsinger, T. Schoeller, and E. Bruera, Methadone in the management of cancer pain: a review, Pain, vol.52, issue.2, pp.137-184, 1993.
DOI : 10.1016/0304-3959(93)90125-9

M. Kreek, A. Schecter, C. Gutjahr, and M. Hecht, Methadone use in patients with chronic renal disease, Drug and Alcohol Dependence, vol.5, issue.3, p.197, 1980.
DOI : 10.1016/0376-8716(80)90180-5

K. Herrlin, M. Segerdahl, L. Gustafsson, and E. Kalso, Methadone, ciprofloxacin, and adverse drug reactions, The Lancet, vol.356, issue.9247, pp.2069-70, 2000.
DOI : 10.1016/S0140-6736(00)03409-7

M. Krantz, L. Lewkowiez, and H. Hays, Torsade de pointes associated with very-high-dose methadone
DOI : 10.1016/s1062-1458(02)01053-x

. High-dose-methadone, P. Walker, D. Klein, and L. Kasza, A report of three cases, Pain, vol.103, issue.3, pp.321-325, 2003.

S. Borowsky and C. Lieber, 188-Interaction of methadone and ethanol metabolism

. Disponible-sur, qtdrugs.org/medical-pros/drug-lists/drug-lists.htm 190-Effect of corticosteroids on the expression of cytochromes

E. Mccance-katz, P. Rainey, P. Jatlow, and G. Friedland, Methadone Effects on Zidovudine Disposition (AIDS Clinical Trials Group 262), Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol.18, issue.5, pp.435-478, 1998.
DOI : 10.1097/00042560-199808150-00004

C. , P. Walker, J. L. Palmer, and E. Bruera, The Effect of Oral Methadone on the QTc Interval in Advanced Cancer Patients: A Prospective Pilot Study Suresh Reddy, JOURNAL OF PALLIATIVE MEDICINE, vol.13, issue.1, pp.33-38, 2010.

S. Mercadante, A. Casuccio, A. Agnello, R. Serretta, L. Calderone et al., Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home., Journal of Clinical Oncology, vol.16, issue.11, pp.3656-3661, 1998.
DOI : 10.1200/JCO.1998.16.11.3656

F. Ripamonti, L. De-conno, M. Groff, J. Belzile, J. Pereira et al., Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: Comparison of two clinical experiences, Annals of Oncology, vol.9, issue.1, pp.79-83, 1998.
DOI : 10.1023/A:1008263910494

J. Santiago-palma, N. Khojainova, and C. Kornick, Intravenous methadone in the management of chronic cancer pain, Cancer, vol.82, issue.7, pp.1919-1944, 2001.
DOI : 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3

E. Bruera, J. Pereira, and S. Watanabe, Opioid rotation in patients with cancer pain: A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine, Cancer, vol.35, issue.4, pp.852-859, 1996.
DOI : 10.1002/j.1552-4604.1995.tb04743.x

P. Lawlor, K. Turner, J. Hanson, and E. Bruera, Dose ratio between morphine and methadone in patients with cancer pain, Cancer, vol.47, issue.6, pp.1167-73, 1998.
DOI : 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3

URL : http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3/pdf

M. Benítez-rosario, M. Feria, A. Salinas-martín, L. Martínez-castillo, and J. Martín-ortega, Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain, Cancer, vol.72, issue.12, pp.2866-73, 2004.
DOI : 10.1016/S0304-3959(97)00018-3

N. Moryl, J. Santiago-palma, and C. Kornick, Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain, Pain, vol.96, issue.3, pp.325-333, 2002.
DOI : 10.1016/S0304-3959(01)00465-1

S. Mercadante, P. Ferrera, and P. Villari, Rapid Switching Between Transdermal Fentanyl and Methadone in Cancer Patients, Journal of Clinical Oncology, vol.23, issue.22, pp.5229-5263, 2005.
DOI : 10.1200/JCO.2005.13.128

K. Bhimji, Opioid Rotation from Methadone: Fraught with Difficulties, Journal of Pain and Symptom Management, vol.29, issue.4
DOI : 10.1016/j.jpainsymman.2005.02.006

P. Walker, S. Palla, B. Pei, G. Kaur, K. Zhang et al., Switching from Methadone to a Different Opioid: What Is the Equianalgesic Dose Ratio?, Journal of Palliative Medicine, vol.11, issue.8
DOI : 10.1089/jpm.2007.0285

S. Mercadante, A. Casuccio, and L. Calderone, Rapid Switching From Morphine to Methadone in Cancer Patients With Poor Response to Morphine, Journal of Clinical Oncology, vol.17, issue.10, pp.3307-3312, 1999.
DOI : 10.1200/JCO.1999.17.10.3307

J. Morley and M. Makin, The use of methadone in cancer pain poorly responsive to other opioids, Pain reviews, vol.5, issue.1, pp.51-58, 1998.
DOI : 10.1191/096813098673619329

C. Scholes, N. Gonty, and I. Trotman, Methadone titration in opioid-resistant cancer pain, European Journal of Cancer Care, vol.4, issue.1, pp.26-35, 1999.
DOI : 10.1016/S0305-7372(96)90075-4

P. Daeninick and E. Bruera, Reduction in Constipation and Laxative Requirements Following Opioid Rotation to Methadone, A Report of Four Cases, Journal of Pain and Symptom Management, vol.18, issue.4, pp.303-309, 1999.
DOI : 10.1016/S0885-3924(99)00086-X

P. J. Daeninck, . Md, F. Msc, and E. Bruera, Reduction in Constipation and Laxative Requirements Following Opioid Rotation to Methadone, A Report of Four Cases, Journal of Pain and Symptom Management, vol.18, issue.4, pp.303-309, 1999.
DOI : 10.1016/S0885-3924(99)00086-X

G. Hunt and E. Bruera, Respiratory depression in a patient receiving oral methadone for cancer pain, Journal of Pain and Symptom Management, vol.10, issue.5
DOI : 10.1016/0885-3924(95)00021-P

E. Ahmed and B. Eduardo, Methadone-Induced Respiratory Depression in a Patient with a History of Alcoholism, JOURNAL OF PALLIATIVE MEDICINE, vol.8, issue.5, pp.1062-1066, 2005.

C. Kornick, M. Kilborn, and J. Santiago-palma, QTc interval prolongation associated with intravenous methadone, Pain, vol.105, issue.3, pp.499-506, 2003.
DOI : 10.1016/S0304-3959(03)00205-7

J. Maxwell and T. Pullum, Deaths of clients in methadone treatment in Texas: 1994???2002, Drug and Alcohol Dependence, vol.78, issue.1, pp.73-81, 2005.
DOI : 10.1016/j.drugalcdep.2004.09.006

R. G. Newman, Methadone for Pain: Limited Evidence, Tenuous Guidelines, The Journal of Pain, vol.10, issue.7, pp.774-775, 2009.
DOI : 10.1016/j.jpain.2009.04.010

S. Watanabe, M. Belzile, N. Kuehn, J. Hanson, and E. Bruera, Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations, Cancer Treatment Reviews, vol.22, pp.131-137, 1996.
DOI : 10.1016/S0305-7372(96)90075-4

T. -brechner and P. Ganz, Combination therapy with ibuprofen and methadone for chronic cancer pain Ferrer

L. Grochow, V. Sheidler, S. Grossman, and L. Green, Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized, double-blind study, Pain, vol.38, issue.2, pp.151-158, 1989.
DOI : 10.1016/0304-3959(89)90233-9

S. Matts, C. Swan, and B. Wharton, Double Blind Trial of Dextromoramide, Methadone and Pethidine in the Treatment of Severe Pain, Postgraduate Medical Journal, vol.40, issue.460, pp.103-108, 1964.
DOI : 10.1136/pgmj.40.460.103

V. Ventafridda, C. Ripamonti, M. Bianchi, A. Sbanotto, D. Conno et al., A randomized study on oral administration of morphine and methadone in the treatment of cancer pain, Journal of Pain and Symptom Management, vol.1, issue.4, pp.203-210, 1986.
DOI : 10.1016/S0885-3924(86)80042-2

A. Vallerand, S. Hasenau, T. Templin, and D. Collins-bohler, Disparities Between Black and White Patients with Cancer Pain: The Effect of Perception of Control over Pain, Pain Medicine, vol.6, issue.3, pp.242-50, 2005.
DOI : 10.1111/j.1526-4637.2005.05038.x

R. Ramousse, L. Berre, M. Le-guelte, and L. , 266-Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system, 1996.

L. Douleurs-neuropathiques-chroniques, diagnostic, évaluation, traitement en médecine ambulatoire Recommandation pour la pratique clinique de la Société Française d'Étude et de Traitement de la Douleur Douleur analg, Management of neuropathic pain Troels S Jensen, Nanna Brix Finnerup In Pain 2010 an updated review, refresher course syllabus, pp.1-16, 2010.

Q. Place, P. Année, T. Le-diplôme-d-'état, . De, . En et al., Ghislain né le 15 Mars 1973 à Paris 270-Low dose of methadone has an analgesic effect in neuropathic pain: a double blind randomized controlled crossover trial, 2006.

R. H. Dworkina, D. C. Turkb, and J. T. Farrarc, Core outcome measures for chronic pain clinical trials: IMMPACT recommendations, Pain, vol.113, issue.1, pp.9-19, 2005.
DOI : 10.1016/j.pain.2004.09.012

B. Annexe, Constipation sous opioïde recommandantion par la Société Française d'Accompagnement et de Soins Palliatifs prise en charge médicale

.. De-douleurs and .. Généralité, ???????????page 10 I-1-1, Description par temporalité................??????????????, p.11

C. La-douleur, page 12 I-2-1page 12 I-2-2. Epidémiologie : l'enjeu de la douleur dans le cancerpage 12 I-2-2-1. Avant, ????????????????.??.page 13 I-2-2-2. Après 1986 ................?????????????????.?, p.13, 1986.

L. , .. ??, I. Les-opioïdes, .. ?????????-historique????????????, .. ??????????-'hydromorphone? et al., ??page 17 II-1???????????page 18 II-2. Les différentes molécules d'opioïdes??????????.page 18 II-2-1, Transdermique...........................???....??????????, pp.22-24

L. Méthadone and ?. , page 27 II-2-6-1. Forme buvable??????????????, Forme gélule????????????..................................?, pp.27-29

L. Effets-indésirables-des-traitements-opioïdes, ?. La-somnolence, and ?. , ???.page 30 II-4-1. La sédation, p.31

.. La-confusion-et-les-hallucinations, page 32 II-4-4, pp.32-36

I. La-rotation-des-opioïdes and .. , page 35 III-1. Introduction : définitionpage 36 III-2. Pourquoi faire une rotation, pp.37-39

V. Utilisation-de-la-méthadone-en-clinique, .. Un-opioïde-À-la-méthadone, and .. , .page 59 V-1. Sûreté d'utilisationpage 60 V-2, ., pp.63-66

.. Utilisation-de-la-méthadone-en-pratique and ?. , page 68 V-4-1. Naïf ou rotation.page 68 V-4-2. Les différents modèles d'instauration proposés : stop and go ou graduelle, systématique ou ab libitum, p.68

V. Critique-des-données-de-la-littérature and .. , page 83 VI-1. Manque de données des études, Du caractère peu formel et de la variabilité des pratiques des études en algologie et leurs limites, pp.84-86

V. Etude and .. , .page 87 VII-1. Introductionpage 88 VII-3page 94 VII-3-1. Description de la population, Les traitements antalgiques avant la rotation, pp.88-90

.. Sûreté-d-'utilisation, .page 106 VII-3-3-2.page 107 VII-3-3-2-1. Retour à domicilepage 107 VII-3-3-2-2. Délai entre l'introduction de méthadone et la sortie de l'hôpitalpage 107 VII-3-4. Analyses des différentes variables pouvant influer sur les caractéristiques d'utilisation de la méthadone Recherche d'une significativité entre la méthadone à J7 et J28 et la durée d'exposition préalable aux opioïdes Recherche d'une significativité entre la méthadone à J7 et J28 et la survenue d'effets secondaires Analyses des différentes variables pouvant influencer sur la fréquence de survenue des effets secondaires, pp.106-109